Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348895 | 0.89 | SCD (0.68) | SCDTP53TSHR | |
| SCHEMBL244209 | 0.86 | SCD (0.76) | SCDKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL243569 | 0.86 | SCD (0.83) | SCDTP53 | |
| SCHEMBL348996 | 0.82 | ALDH1A1 (0.47) | SCDKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL348527 | 0.81 | SCD (0.83) | SCD | |
| SCHEMBL243812 | 0.81 | SCD (0.67) | SCDKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL244783 | 0.79 | SCD (0.93) | SCDTP53 | |
| SCHEMBL12171629 | 0.79 | SCD (0.53) | SCDTP53MEN1KMT2ATSHR | |
| SCHEMBL348691 | 0.78 | ALDH1A1 (0.49) | SCDKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL244748 | 0.77 | SCD (0.62) | SCDKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885TP53 4010/4885KDM4E 683/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885TP53 4010/4885KDM4E 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.